IPP Bureau
Dr Reddys Laboratories reports Q2 FY26 consolidated PAT at Rs. 1,437.2 Cr
By IPP Bureau - October 27, 2025
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
Health Minister Nadda addresses 50th convocation of AIIMS New Delhi
By IPP Bureau - October 27, 2025
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission
By IPP Bureau - October 27, 2025
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors
By IPP Bureau - October 27, 2025
The event will be attended by 35,000+ industry professionals
Novartis to acquire Avidity Biosciences for $12 billion
By IPP Bureau - October 27, 2025
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million
By IPP Bureau - October 27, 2025
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
By IPP Bureau - October 27, 2025
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Lilly buys Adverum for its phase 3-stage eye disease gene therapy
By IPP Bureau - October 27, 2025
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030
By IPP Bureau - October 27, 2025
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Syngene International expands capabilities with new bioconjugation suite in Bengaluru
By IPP Bureau - October 25, 2025
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Quest Diagnostics reports strong third quarter 2025 results and raises full-year guidance
By IPP Bureau - October 25, 2025
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
By IPP Bureau - October 25, 2025
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors
By IPP Bureau - October 25, 2025
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Europe is putting vital medicines at risk by allowing ‘carbon heavy’ imports from the Far East: INEOS
By IPP Bureau - October 25, 2025
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
.jpg "Cipla to sell Lilly's weight-loss drug under new brand in India")
Cipla to sell Lilly's weight-loss drug under new brand in India
By IPP Bureau - October 24, 2025
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
